Purpose: The objective of this retrospective pilot study was to evaluate the effectiveness of Gabapentin in patients with primary burning mouth syndrome (BMS).
INTRODUCTION
Burning mouth syndrome (BMS) is a condition that is diagnosed based on the presence of an oral burning or similar dysesthesia in the absence of other dental or medical causes. 1) Its true prevalence is uncertain, which an estimated incidence of the condition of 0.7%-4.6% in the general population and a predominance among women. [2] [3] [4] [5] The tongue is the primary location of the burning complaint in the majority of cases, but BMS can also involve the lips, palate, and gingival. 6) BMS be classified into 2 clinical forms: "primary BMS" and "secondary BMS." 7) The primary BMS for which organic local or systemic causes cannot be ·Use of certain medications associated with BMS (for example, angiotensin converting enzyme inhibitors)
·Patients treated and being treating with psychological therapies ·History of an allergy to dental materials
Dose Escalations and Pain Assessment
Gabapentin was administered at a starting dose of 300 mg/day, slowly titrated up to maximum of 1,800 mg/day.
The mean dose was 900±374.16 mg/day. All patients were treated for 4 weeks. Pain was assessed by patients on an 11-point numerical rating score system (0 to 10) before and after treatment.
Statistical Analysis
The categorical variables were summarized as counts and 
RESULTS
Of the 10 subjects included in this study, 8 12)
The objective of this pilot study was to evaluate the effectiveness of Gabapentin in patients with primary BMS.
MATERIALS AND METHODS
The study was approved by the Institutional Review
Board of Pusan National University Dental Hospital.
Subjects and Treatment Methods
This study was conduted at the Department of Oral (Table 1) . Ultimately, 10 patients (8 women and 2 men) met the inclusion criteria with definitive diagnosis of primary BMS according to the criteria of Scala et al. 7) also the exclusions criteria were as 18) reported pilot study. According to the authors, Gabapentin has little or no effect for BMS. However, this study is an open-label study with small sample.
Therefore, before randomized controlled study with sufficient sample, we conducted retrospective pilot study.
The results of this pilot study also suggest that Gabapentin are not beneficial for BMS treatment. Only 2 patients (20%) obtained more 50% reduction in BMS symptoms. Such results may be explained as follows: first, possible explanation that the dosage was too small or that the duration of treatment was too short. And the number of patients was too small to detect a significant treatment effect. Second, such results also may be explained by the ambiguity of the cause of BMS: primary BMS cannot be caregorized into a single pain type (neuropathic pain).
This pilot study provides no preliminary evidence that Gabapentin has effect in the management of BMS. However, further research (well-designed, randomized and controlled trial with large sample) would be needed to investigate the efficacy of Gabapentin in treatment of BMS.
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patients reported no reduction in pain symptoms. One patient reported that symptoms were worsening. After treatmet, only 2 patients obtained more 50% reduction of pain score ( Table 2) .
Average pain score before treatment was 6.3±2.26 (range, 
